Ailani J, Burch R, Robbins M (2021) The American headache society consensus statement: update on integrating new migraine treatments into clinical practice. Headache 61(7):1021–1039. https://doi.org/10.1111/head.14153
Article
PubMed
Google Scholar
Mayans L, Walling A (2018) Acute migraine headache: treatment strategies. Am Fam Physician 97(4):243–251
PubMed
Google Scholar
Stovner L, Nichols E (2016) GBD 2016 headache collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol 17(11):954–976. https://doi.org/10.1016/S1474-4422(18)30322-3
Article
Google Scholar
Berra E, Sances G, De Icco R et al (2015) Cost of chronic and episodic migraine: a pilot study from a tertiary headache Centre in northern Italy. J Headache Pain 16(1):50. https://doi.org/10.1186/s10194-015-0532-6
Article
PubMed Central
Google Scholar
Blumenfeld A, Varon S, Wilcox T, Buse DC, Kawata AK, Manack A, Goadsby PJ, Lipton RB (2011) Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the international burden of migraine study (IBMS). Cephalalgia 31(3):301–315. https://doi.org/10.1177/0333102410381145
Article
CAS
PubMed
Google Scholar
Brown J, Neumann P, Papadopulos G et al (2008) Migraine frequency and health utilities: findings from a multisite survey. Value Health 11(2):315–321. https://doi.org/10.1111/j.1524-4733.2007.00246.x
Article
PubMed
Google Scholar
Burch R, Rizzoli P, Loder E (2018) The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies. Headache 58(4):496–505. https://doi.org/10.1111/head.13281
Article
PubMed
Google Scholar
Buse D, Manack A, Fanning K et al (2012) Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention study. Headache 52(10):1456–1470. https://doi.org/10.1111/j.1526-4610.2012.02223.x
Article
PubMed
Google Scholar
Buse DC, Fanning KM, Reed ML, Murray S, Dumas PK, Adams AM, Lipton RB (2019) Life with migraine: effects on relationships, career, and finances from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache 59(8):1286–1299. https://doi.org/10.1111/head.13613
Article
PubMed
PubMed Central
Google Scholar
Doane MJ, Gupta S, Fang J, Laflamme AK, Vo P (2020) The humanistic and economic burden of migraine in Europe: a cross-sectional survey in five countries. Neurol Ther 9(2):535–549. https://doi.org/10.1007/s40120-020-00196-2
Article
PubMed
PubMed Central
Google Scholar
Doane MJ, Gupta S, Vo P, Laflamme AK, Fang J (2019) Associations between headache-free days and patient-reported outcomes among migraine patients: a cross-sectional analysis of survey data in Europe. Pain Ther 8(2):203–216. https://doi.org/10.1007/s40122-019-0133-1
Article
PubMed
PubMed Central
Google Scholar
Ford J, Jackson J, Milligan G et al (2017) A real-world analysis of migraine: a cross-sectional study of disease burden and treatment patterns. Headache J Head Face Pain 57(10):1532–1544. https://doi.org/10.1111/head.13202
Article
Google Scholar
Lipton R, Manack Adams A, Buse D et al (2016) A comparison of the chronic migraine epidemiology and outcomes (CaMEO) study and American Migraine Prevalence and Prevention (AMPP) study: demographics and headache-related disability. Headache 56(8):1280–1289. https://doi.org/10.1111/head.12878
Article
PubMed
PubMed Central
Google Scholar
Silberstein SD, Lee L, Gandhi K, Fitzgerald T, Bell J, Cohen JM (2018) Health care resource utilization and migraine disability along the migraine continuum among patients treated for migraine. Headache 58(10):1579–1592. https://doi.org/10.1111/head.13421
Article
PubMed
Google Scholar
Stafford M, Hareendran A, Ng-Mak D, Insinga R, Xu R, Stull D (2012) EQ-5D™-derived utility values for different levels of migraine severity from a UK sample of migraineurs. Health Qual Life Outcomes 10(1):65. https://doi.org/10.1186/1477-7525-10-65
Article
PubMed
PubMed Central
Google Scholar
Wang S, Wang P, Fuh J, Peng KP, Ng K (2012) Comparisons of disability, quality of life, and resource use between chronic and episodic migraineurs: a clinic-based study in Taiwan. Cephalalgia 33(3):171–181. https://doi.org/10.1177/0333102412468668
Article
PubMed
Google Scholar
Croop R, Goadsby PJ, Stock DA et al (2019) Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet (London, England) 394(10200):737–745
Article
CAS
Google Scholar
Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ (2019) Rimegepant, an Oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med 381(2):142–149. https://doi.org/10.1056/NEJMoa1811090
Article
CAS
PubMed
Google Scholar
Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ (2014) BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia 34(2):114–125. https://doi.org/10.1177/0333102413500727
Article
PubMed
Google Scholar
Croop R, Lipton RB, Kudrow D et al (2021) Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet (London, England) 397(10268):51–60
Article
CAS
Google Scholar
Gao B, Yang Y, Wang Z, Sun Y, Chen Z, Zhu Y, Wang Z (2019) Efficacy and safety of Rimegepant for the acute treatment of migraine: evidence from randomized controlled trials. Front Pharmacol 10:1577. https://doi.org/10.3389/fphar.2019.01577
Article
CAS
PubMed
Google Scholar
Pharmaceuticals B (2021) NURTEC ODT (rimegepant) orally disintegrating tablets Prescribing Information. FDA, New Haven, CT
Google Scholar
Johnston K, Harris L, Powell L et al (2021) Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000-201) (poster P-144). Headache J Head Face Pain 61(S1):1–178
Article
Google Scholar
Lipton RB, Serrano D, Nicholson RA, Buse DC, Runken MC, Reed ML (2013) Impact of NSAID and Triptan use on developing chronic migraine: results from the a merican migraine prevalence and prevention (AMPP) study. Headache J Head Face Pain 53(10):1548–1563. https://doi.org/10.1111/head.12201
Article
Google Scholar
Schwedt TJ, Alam A, Reed ML, Fanning KM, Munjal S, Buse DC, Dodick DW, Lipton RB (2018) Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study. J Headache Pain 19(1):1–9. https://doi.org/10.1186/s10194-018-0865-z
Article
CAS
Google Scholar
Papanicolaou S, Sykes D, Mossialos E (2004) EMEA and the evaluation of health-related quality of life data in the drug regulatory process. Int J Technol Assess Health Care 20(3):311–324. https://doi.org/10.1017/S0266462304001138
Article
PubMed
Google Scholar
Stalmeier PF, Chapman GB, de Boer AG, van Lanschot JJ (2001) A fallacy of the multiplicative QALY model for low-quality weights in students and patients judging hypothetical health states. Int J Technol Assess Health Care 17(4):488–496. https://doi.org/10.1017/S026646230110704X
Article
CAS
PubMed
Google Scholar
Grey RR, Townsend RJ, Sanders CA (1995) Outcomes measurement. The key to the appropriate use of pharmaceuticals. Int J Technol Assess Health Care 11(3):472–484. https://doi.org/10.1017/S0266462300008680
Article
CAS
PubMed
Google Scholar
Mahon R, Huels J, Hacking V, Cooney P, Danyliv A, Vudumula U, Vadapalle S, Vo P, Maniyar FH, Palmer S, Goadsby PJ (2020) Economic evaluations in migraine: systematic literature review and a novel approach. J Med Econ 23(8):864–876. https://doi.org/10.1080/13696998.2020.1754840
Article
PubMed
Google Scholar
Asseburg C, Peura P, Oksanen T, Turunen J, Purmonen T, Martikainen J (2012) Cost-effectiveness of oral triptans for acute migraine: mixed treatment comparison. Int J Technol Assess Health Care 28(4):382–389. https://doi.org/10.1017/S0266462312000517
Article
PubMed
Google Scholar
Lofland JH, Nash DB (2005) Oral serotonin receptor agonists: a review of their cost effectiveness in migraine. PharmacoEconomics 23(3):259–274. https://doi.org/10.2165/00019053-200523030-00006
Article
CAS
PubMed
Google Scholar
McCormack PL, Foster RH (2005) Rizatriptan: a pharmacoeconomic review of its use in the acute treatment of migraine. PharmacoEconomics 23(12):1283–1298. https://doi.org/10.2165/00019053-200523120-00011
Article
CAS
PubMed
Google Scholar
Atlas S, Touchette D, Agboola F, et al. Acute Treatments for Migraine: Effectiveness and Value. Institute for Clinical and Economic Review, February 25. 2020; http://icer-review.org/material/acute-migraine-evidence-report/. Accessed 5 Aug 2020
ClinicalTrials.gov. NCT03266588: A Multicenter, Open Label Long-Term Safety Study of BHV-3000 in the Acute Treatment of Migraine. 2020; https://clinicaltrials.gov/ct2/show/NCT03266588. Accessed 6 Oct 2020
Lipton RB, Berman G, Kudrow D et al (2019) Long-term, open-label safety study of Rimegepant 75 mg for the treatment of migraine (BHV3000-201): interim analysis of safety and exploratory efficacy (IHC-PO-127). Cephalalgia 36(suppl):1–337
Google Scholar
The International Classification of Headache Disorders (2013) 3rd edition (beta version). Cephalalgia 33(9):629–808. https://doi.org/10.1177/0333102413485658
Article
Google Scholar
Dodick D, Goadsby P, Lu K et al (2019) Ubrogepant achieves early pain relief for the acute treatment of migraine. Annual meeting of the American headache society (AHS), Philadelphia, PA
Google Scholar
Bagley C, Rendas-Baum R, Maglinte G et al (2012) Validating migraine-specific quality of life questionnaire v2.1 in episodic and chronic migraine. Headache 52(3):409–412. https://doi.org/10.1111/j.1526-4610.2011.01997.x
Article
PubMed
Google Scholar
Jhingran P, Osterhaus J, Miller D, Lee J, Kirchdoerfer L (1998) Development and validation of the migraine-specific quality of life questionnaire. Headache 38(4):295–302. https://doi.org/10.1046/j.1526-4610.1998.3804295.x
Article
CAS
PubMed
Google Scholar
Gillard P, Devine B, Varon S, Liu L, Sullivan S (2012) Mapping from disease-specific measures to health-state utility values in individuals with migraine. Value Health 15(3):485–495. https://doi.org/10.1016/j.jval.2011.12.007
Article
PubMed
Google Scholar
Biohaven Pharmaceutical Holding Company Limited. Protocol BHV3000–201: A Multicenter, Open Label Long-Term Safety Study of BHV-3000 in the Acute Treatment of Migraine. https://clinicaltrials.gov/ProvidedDocs/88/NCT03266588/Prot_000.pdf. Accessed 2 Jan 2022.
Berman G, Croop R, Kudrow D, Halverson P, Lovegren M, Thiry AC, Conway CM, Coric V, Lipton RB (2020) Safety of Rimegepant, an Oral CGRP receptor antagonist, plus CGRP monoclonal antibodies for migraine. Headache 60(8):1734–1742. https://doi.org/10.1111/head.13930
Article
PubMed
PubMed Central
Google Scholar
Mullin K, Kudrow D, Croop R, Lovegren M, Conway CM, Coric V, Lipton RB (2020) Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy. Neurology 94(20):e2121–e2125. https://doi.org/10.1212/WNL.0000000000008944
Article
CAS
PubMed
PubMed Central
Google Scholar
Hong P, Liu Y (2017) Calcitonin gene-related peptide antagonism for acute treatment of migraine: a meta-analysis. Int J Neurosci 127(1):20–27. https://doi.org/10.3109/00207454.2015.1137915
Article
CAS
PubMed
Google Scholar
Agboola F, Atlas S, Touchette D et al (2020) The effectiveness and value of novel acute treatments for migraine. J Managed Care Specialty Pharm 26(11):1456–1462. https://doi.org/10.18553/jmcp.2020.26.11.1456
Article
Google Scholar
Ha DK, Kim MJ, Han N, Kwak JH, Baek IH (2021) Comparative efficacy of Oral calcitonin-gene-related peptide antagonists for the treatment of acute migraine: updated Meta-analysis. Clin Drug Investig 41(2):119–132. https://doi.org/10.1007/s40261-020-00997-1
Article
CAS
PubMed
Google Scholar
Croop R, Ivans A, Stock D et al (2018) A phase 1 study to evaluate the bioequivalence of oral tablet and orally dissolving tablet formulations of rimegepant in healthy adult subjects under fasting conditions. Headache 58(8):1303–1304
Google Scholar
Ferrari M, Goadsby P, Roon K, Lipton RB (2002) Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 22(8):633–658. https://doi.org/10.1046/j.1468-2982.2002.00404.x
Article
CAS
PubMed
Google Scholar
American Headache Society, American Migraine Foundation. ICER OPEN COMMENT PERIOD ON: ACUTE TREATMENTS FOR MIGRAINE: DRAFT EVIDENCE REPORT. 2019. https://icer.org/wp-content/uploads/2020/10/ICER-Acute_Migraine_Draft_Report_Comments_Folio.pdf. Accessed 2 Jan 2022.
Johnston KM, L'Italien G, Harris L et al (2021) Novel acute therapies in the treatment of migraine: impact of re-dosing on cost–utility outcomes. J Med Econ 24(1):512–513. https://doi.org/10.1080/13696998.2021.1915600
Article
PubMed
Google Scholar
Brandes JL, Klise S, Krege JH, Case M, Khanna R, Vasudeva R, Raskin J, Pearlman EM, Kudrow D (2019) Interim results of a prospective, randomized, open-label, phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study). Cephalalgia 39(11):1343–1357. https://doi.org/10.1177/0333102419864132
Article
PubMed
PubMed Central
Google Scholar